30 April 2020
Visiongain has launched a new pharma report Global Biosimilars and Follow-On Biologics Market 2020-2030: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietin’s, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones, Blood Disorders, Growth Hormone Deficiency, Autoimmune Diseases, Cancer, Diabetes, Infectious Diseases.
Many blockbusters branded innovator drugs are losing patent protection in the coming years. Some have already lost the market exclusivity and hence are prone to share their market space with the generic versions. Some examples include Roche’s Herceptin and Avastin, Amgen’s Enbrel, AbbVie’s Humira, etc. Billions of dollars are at stake for the branded pharmaceuticals market. This has led to a strong push for the biosimilar manufacturers. As such, both established and local pharmaceutical and biotechnology companies are making their way in this potential market.
The lead analyst of the report commented "As mentioned above, rapid growth in the biosimilars market during the period 2020-2030 will be a driven by a wide range of different factors. This will be primarily driven by the demand for lower cost alternatives to biologics by patients, doctors, healthcare payers and nations. Patent expiries for leading branded biologics will allow for the launch of a wider range of biosimilars in both developed and emerging markets."
Leading companies featured in the report include Amgen Inc, Biocon Limited, Celltrion Healthcare Co. Ltd, Dong-A Socio Holdings Co. Ltd, Dr.Reddy's Labs (DRL), F. Hoffmann-La Roche Ltd. and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.